In four phase III studies in patients with colorectal, renal and lung cancer, the pretreatment levels of VEGF-A were associated with the overall survival but did not predict response to the therapy with bevacizumab [111], indicating a prognostic rather than a predictive value of circulation VEGF. The gene discussed is VEGFA; the disease is lung cancer.